Lupin Gains FDA Approval for Generic Dapagliflozin, Challenging AstraZeneca’s Farxiga
Event summary
- Lupin received FDA approval for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg, on April 7, 2026.
- The FDA approved Lupin's Dapagliflozin Tablets as bioequivalent to AstraZeneca’s Farxiga® for the same indications.
- Lupin is a global pharmaceutical leader with operations in over 100 markets and 15 manufacturing sites worldwide.
The big picture
Lupin’s FDA approval for Dapagliflozin Tablets marks a strategic move into the competitive anti-diabetic market, directly challenging AstraZeneca’s Farxiga. This approval strengthens Lupin’s position in the U.S. generics market, where it already holds a strong foothold across multiple therapy areas. The approval could accelerate Lupin’s revenue growth, particularly if it can capture significant market share from Farxiga.
What we're watching
- Market Share Impact
- How Lupin’s entry will affect AstraZeneca’s Farxiga market share in the U.S.
- Pricing Dynamics
- Whether Lupin can sustain competitive pricing while maintaining profitability.
- Regulatory Compliance
- The pace at which Lupin can expand its generic portfolio under FDA scrutiny.
Our editorial coverage:
Related topics